This article has been updated to include information about an FDA-approved companion diagnostic for pralsetinib.
NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to Blueprint Medicines and Genentech's Gavreto (pralsetinib) for metastatic, RET fusion-positive, non-small cell lung cancer.